Caspian: Os Results from a Randomised Phase 3 Study  of First-Line Durvalumab ± Tremelimumab + Chemotherapy  in ES-SCLC

Alt, Jürgen; Armstrong, Jon; Bondarenko, Igor; Byrne, Natalie; Chen, Yuanbin; Conev, Nicolay V; Goldman, Jonathan; Havel, Libor; Hochmair, Maximilian J; Hotta, Katsuyuki; Jiang, Haiyi; Kazarnowicz, Andrzej; LI, Jun Ho; Losonczy, György; Paz-Ares, Luis; Poltoratskiy, Artem; Ponce, Santiago; Reinmuth, Niels; Shire, Norah; Statsenko, Galina; Trukhin, Dmytro; Verderame, Francesco; Voitko, Oleksandr; Özgüroğlu, Mustafa

Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy in ES-SCLC

Authors: Jürgen Alt
Jon Armstrong
Igor Bondarenko
Natalie Byrne
Yuanbin Chen
Nicolay V Conev
Jonathan Goldman
Libor Havel
Maximilian J Hochmair
Katsuyuki Hotta
Haiyi Jiang
Andrzej Kazarnowicz
Jun Ho LI
György Losonczy
Luis Paz-Ares
Artem Poltoratskiy
Santiago Ponce
Niels Reinmuth
Norah Shire
Galina Statsenko
Dmytro Trukhin
Francesco Verderame
Oleksandr Voitko
Mustafa Özgüroğlu
Publication date: 1 January 2020
Publisher: KARGER, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND

Abstract

Immune checkpoint blockade targeting the PD-1/PD-L1 pathway in combination with platinum-based chemotherapy (CT) has demonstrated improved clinical outcomes in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab ± Tremelimumab in combination with etoposide and platinum-based CT (EP) as first-line treatment for pts with ES-SCLC. Results will be presented at WCLC 2019 including OS, key secondary endpoints, safety and tolerability